Kornimate/medical-research-clean huggingface dataset:
intratympanic injection of dexamethasone with hyaluronic acid in treatment of sudden sensorineural hearing loss

Conditions: Sudden Sensorineural Hearing Loss (SSNHL)

Summary: * to evaluate efficacy of intratympanic injection of dexamethasone and hyaluronic acid mixture as a treatment modality in cases of sudden sensorineural hearing loss (ssnhl). * to compare outcomes of intratympanic injection of dexamethasone and hyaluronic acid mixture to dexamethasone alone in treatment of ssnhl.

sudden sensory neural hearing loss (ssnhl) is defined as sensorineural hearing loss of at least 30 db over 3 consecutive frequencies within 3 days. different treatment modalities have been used in treatment of ssnhl including systemic corticosteroids alone or in combination with vasodilators as pentoxifylline and hydroxyethylstarch (hes) or low molecular weight dextran, hyperbaric oxygen therapy \& plasmapheresis. intratympanic (it) dexamethasone application has shown significantly higher perilymph steroid concentrations with lower systemic concentrations, thus avoiding the side effects associated with the systemic route. it has been used with varying results for the treatment of meniere's disease, ssnhl, low frequency hearing loss and tinnitus. after it injection, the drug concentration in the inner ear depends on the drug being in contact with the round window membrane (rwm), absorbing it from the middle ear into the inner ear. however, large amount of the injected drugs are either absorbed by the middle ear mucosa or evacuated via the eustachian tube. it has been postulated that combining the drug with a biodegradable material will prolong its availability in the middle ear and/or aid its diffusion across the rwm. between these materials, hyaluronic acid (ha) is a natural product normally present is humans' perilymph in small amounts along with many other tissues throughout the body. several postulations have been given to ha mechanism of action in drug delivery in the middle ear either by its osmotic effect on the perilymph, modulating rwm permeability or altering blood viscosity thus increasing blood and oxygen delivery.

Eligibility criteria:
inclusion criteria: 1. adult patients (aged 18 and over) 2. patients with sudden sensory neural hearing loss (ssnhl) exclusion criteria: 1. patients with middle or external ear pathology. 2. patient with history of traumatic skull base fracture. 3. patients with previous ear surgery. 4. patients with other neurological symptoms or signs (other cranial nerves affection).

Keywords: hyaluronic acid dexamethasone ssnhl sudden sensorineural hearing loss
a mobile health solution for homework during cbt

Conditions: Anxiety; Depression; Posttraumatic Stress Disorder

Summary: the purpose of this study is to preliminarily evaluate a web-based app to improve provider implementation and patient engagement in homework (i.e., between-session practice of skills learned during therapy) during child mental health treatment by conducting a small-scale feasibility trial in community practice settings comparing cognitive behavioral therapy (cbt) to cbt enhanced with the app.


Eligibility criteria:
inclusion criteria: providers: * english-speaking * mental health providers who have obtained at least a master's degree in social work, counseling, clinical psychology, or related field * carry active child mental health treatment caseloads * have a laptop, tablet, or smartphone with internet access youth: * english-speaking * youth ages 7-17 years * clinically elevated anxiety and depression as indicated by a t-score ≥ 65 on the revised children's anxiety and depression scale-25 child version (rcads-25-y) and/or revised children's anxiety and depression scale-25 parent version (rcads-25-p) or total score ≥ 15 on the child and adolescent trauma screen - youth report (cats-y) and/or child and adolescent trauma screen - caregiver report (cats-p) * have a laptop, tablet, or smartphone with internet access caregivers: * english-speaking * adult (≥18 years old) * caregivers of a youth who meets eligibility criteria * have internet and smartphone access. exclusion criteria: youth with self- or caregiver-reported: * active psychotic symptoms (e.g., hallucinations, delusions) * significant cognitive disability, developmental delays, or pervasive developmental disorder.

Keywords: mhealth mental health youth mental health adolescent mental health homework
continuous glucose monitoring with immediate or delayed counseling feedback

Conditions: Type2 Diabetes

Summary: this study is designed to explore the effect of feedback counseling using professional continuous glucose monitoring on glycemic control, self-efficacy, and self-management behaviors among middle aged and older adults with poor controlled type 2 diabetes mellitus. this study also explores the difference on timing of feedback after continuous glucose monitoring exam.

after scheduled routine professional continuous glucose monitoring (cgm) exam, participants in both the intervention and control group receive ordinary education and regimen adjustment as indicated based on cgm results. for participants in the intervention group, they will also receive cgm counseling immediately on the day of cgm sensor removal. for participants in the control group, they will receive cgm counseling on the day of routine 3 months outpatient visit. qualitative data are collected through in-depth interview: user expectation, acceptability and satisfaction of cgm are also explored during in-depth interview with a semi-structured questionnaire. quantitative data were collected through validated questionnaires, including evaluation of depression by a short form of the center for epidemiologic studies depression scale revised (ces-d-r), emotional stress by problem areas in diabetes scale (paid), self efficacy by stanford self-efficacy for diabetes (ses), at pretest and 3 months after cgm counseling. anthropometric measurements. body height, body weight, body mass index, and blood pressure were recorded at pre-test and post-test interview. blood tests. routine biochemistry, fasting plasma glucose, hemoglobin a1c (hba1c) are collected within 2 weeks of pretest and posttest day.

Eligibility criteria:
inclusion criteria: * age 45 years old or more at recent outpatient visits; * type 2 diabetic patients followed up at national cheng kung university hospital; * patients planned to receive cgm suggested by primary care physician due to inadequate controlled blood glucose. exclusion criteria: * patients with diagnosis of generalized inflammation, advanced malignancy, end-stage renal disease on regular dialysis, status post renal transplantation, end-stage liver, heart or pulmonary disease; * patients who are taking systemic glucocorticoids; * any acute or chronic inflammatory disease as determined by a leukocyte count over 10,000/mm3 or clinical signs of infection; * patients who could not complete the questionnaires or who could not follow order due to cognitive impairment or in bed-ridden status; * patients diagnosed as thalassemia, glucose-6-phosphate dehydrogenase deficiency, and any other hemoglobinopathies that may influence the accuracy of hemoglobulin a1c measurement were also excluded. patients who received blood transfusion in recent 3 months were also excluded.

Keywords: continuous glucose monitoring immediate feedback counseling delayed feedback counseling
a study to compare the taste and levels in blood plasma of bms-986165 when taken as different formulations by healthy adult participants

Conditions: Healthy Participants

Summary: the purpose of this study is to compare the taste, and the levels in blood plasma of different tablet formulations of bms-986165 when taken by healthy adults.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ecgs, and clinical laboratory determinations in the opinion of the investigator * women and men must agree to follow specific methods of contraception, if applicable exclusion criteria: * any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of/or active liver disease * inability to tolerate oral medication * history of allergy to bms-986165 or related compounds other protocol-defined inclusion/exclusion criteria apply
a study to test the safety and tolerability of long-term ucb0107 administration in study participants with progressive supranuclear palsy

Conditions: Progressive Supranuclear Palsy

Summary: the purpose of the study is to assess the long-term safety and tolerability of ucb0107 in study participants with progressive supranuclear palsy (psp).


Eligibility criteria:
inclusion criteria: * participant meets the criteria for possible or probable progressive supranuclear palsy (psp) richardson's syndrome according to the movement disorder society-psp criteria (hoeglinger et al, 2017) * participant completed the treatment period (regardless of the total number of infusions) in psp003 (nct04185415) * participant can be male or female a) a male participant must agree to use contraception as detailed in the protocol during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period b) a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: i. not a woman of childbearing potential (wocbp) or ii. a wocbp who agrees to follow the contraceptive guidance in the protocol during the treatment period and for at least 6 months after the last dose of study treatment. * participant (or legal representative, as applicable and acceptable by local regulations) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the icf and in this protocol. informed consent must be obtained before initiating any study procedures exclusion criteria: * participant has met a mandatory withdrawal and/or stopping criterion in psp003 (nct04185415) * participant made a suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt) during psp003 (nct04185415), or has current suicidal ideation with at least some intent to act as indicated by a positive response ("yes") to either question 4 or question 5 of the "since last visit" version of the columbia suicide severity rating scale (cssrs) at the day 1 visit. however, participants will not be excluded if, based upon a mental healthcare professional assessment, and the investigator's judgment of benefit/risk, the participant is deemed suitable for receiving study medication

Keywords: progressive supranuclear palsy ucb0107 phase 1b study psp bepranemab
platelet rich plasm versus hyaluronic acid injection in chronic painful shoulder

Conditions: Chronic Shoulder Pain

Summary: aim of this study is to compare between the effect of ultrasound-guided local injection of platelet rich plasma (prp)versus hyaluronic (ha) for the treatment of chronic shoulder pain.

this study was prospective randomized comparative trial on patients with chronic shoulder pain presented at outpatient clinic of physical medicine, rheumatology and rehabilitation department at assiut university hospitals from june 2019 to december 2020. our study started by 70 patient with chronic shoulder pain 20 of them were missed in follow up period, the range of age from 36 - 56 years, history, clinical examination, laboratory investigation, and imaging (x-ray or mri) done for all patient to complete the diagnosis, patient divided randomly into two groups, group (a) included 25 patients were treated by prp injection and group (b) included 25 patients were treated by ha injection, both injections were performed under ultrasound (us) guidance. randomization by sealed envelopes technique, the follow up was at the baseline, 4 weeks and 6 months post injection.

Eligibility criteria:
inclusion criteria: * adult patient age \>18 years. * patients with chronic shoulder pain more than 6 months not responding to medical treatment or physical therapy. * frozen shoulder. * rotator cuff disorders (partial tear). exclusion criteria: * shoulder joint instability or traumatic shoulder pain. * patients with local infection at the shoulder, systemic infection, or inflammatory disease (e.g., rheumatoid arthritis and hepatitis) * patients with a history of diabetes mellitus and malignancy (either hematological or non-hematological). * pregnancy. * patients on anticoagulant therapy. * injection of shoulder with corticosteroids in the preceding 6 months.
genotype-related molecular targets in the vitamin d pathway for spinal disc diseases

Conditions: Intervertebral Disk Degeneration

Summary: the objective of our study will be to analyze the interplay between particular vdr variants and its ligand in cells obtained from intervertebral disc and cartilage endplate and their action on cell proliferation and phenotype maintenance. the identification of novel molecular targets in the vitamin d pathway, potentially promoting pathological alterations of the tissues involved in spinal disc diseases, will allow to develop innovative and more personalized preventive and pharmacological/nutritional therapies.


Eligibility criteria:
inclusion criteria: patients with spinal disc diseases * males and females * 18≤age ≤ 70 years old * italian white * patients with spinal disc diseases that will be surgically treated exclusion criteria: - age \ 70 years old
neurological features during covid19

Conditions: Encephalitis

Summary: description of the neurological impairment: clinico-radiological and electrophysilogical correlations

describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral sars cov2 infection describe the association between neurological, respiratory and dysautonomic determine the prognosis of neurological damages to short and long term.

Eligibility criteria:
inclusion criteria: * pcr sars cov2 positive or ct scan * central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral. * dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, siadh not explained by therapy or a pathology other than sars cov 2 infection exclusion criteria: * contraindication to performing an mri scan * minor * pregnant woman * no follow-up possible at 6 months

Keywords: cranial nerves brainstem dysautonomia
keloid scarring: treatment and pathophysiology

Conditions: Keloid Scar

Summary: to clarify the mechanisms of keloid scar formation. elucidate the action and therapeutic value of 5-fu in keloid scar treatment identify the genetic link with keloid scar formation. quantify the psychological/social impact in keloid scarring patients


Eligibility criteria:
inclusion criteria: * adult ( \> 18 years old). * keloid scarring present. * able to understand and give informed consent. * patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. bbr, abdominoplasty). * patients with a strong familial pedigree of keloid scar formation. exclusion criteria: * open wound at or proximity of the lesion * infected lesion * pregnant or planning pregnancy in the near future * lactating (breast feeding) * abnormal renal or liver function tests * atrophic scars * patient under 18 years of age * immunocompromised * or immunosuppressed

Keywords: scar formation 5-fu genetic link psychological impact social impact
randomized controlled trial of dexmedetomidine for the treatment of intensive care unit (icu) delirium

Conditions: Delirium; Agitation

Summary: the purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium

delirium is a mental disturbance that causes people to be confused and restless for a period of time. we will compare dexmedetomidine to the traditional therapy for treatment of acute delirium. dexmedetomidine does not affect breathing. the traditional drugs might make one sleepy and may slow down breathing. the traditional therapy in this institution for acute delirium is _the use of haloperidol, and/or benzodiazepines. haloperidol is an antipsychotic drug that has calming effect. benzodiazepines are sedatives with calming effect.dexmedetomidine is approved by the food and drug administration (fda) to sedate patients on a breathing machine for 24 hours.

Eligibility criteria:
inclusion criteria: * adults admitted to our surgical icu who do not have any exclusion criteria * eligibility for treatment- development of delirium as defined exclusion criteria: * acute mi (myocardial infarction), * trauma \<24 hours, * head injury, * multiple organ failure, * ef (ejection fraction) \< 30%, * history of hypersensitivity to alpha2 agonist, * history of seizures, map (mean arterial pressure) \<60 mm of hg, * dysrhythmias a/with bradycardia (hr (heart rate) \<50), * need for vasopressors, * acute renal failure with a need for dialysis/cvvh (continuous veno-venous hemofiltration) or liver disease. * women of child bearing age who do not have a documented negative pregnancy test and/or who do not actively use contraception. (documented negative pregnancy test will be a urine pregnancy test obtained on this admission)

Keywords: delirium agitation sedation dexmedetomidine surgical
the internal thoracic artery skeletonization study: a paired, within-patient comparison

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether skeletonization of the internal thoracic artery leads to improved flow, increased length, improved sternal perfusion, and decreased pain and dysesthesia in patients undergoing coronary artery bypass surgery

traditional harvesting of the internal thoracic artery (ita) for use as a conduit in coronary bypass surgery involves the dissection of a rim of tissue surrounding the artery on either side. although the benefits of ita use are well established, there are certain limitations to its routine use. recent studies, primarily observational, have suggested that skeletonization of the ita (i.e. harvesting of the ita alone) may overcome some of these limitations by improving conduit flow, increasing length, and reducing the risk of deep sternal infection in high risk patients. furthermore, skeletonization of the ita can potentially preserve intercostal nerves and reduce post-operative pain and dysesthesias associated with ita harvesting. in order to assess the effects of ita skeletonization, this is a prospective, randomized, within-patient study design in patients undergoing coronary artery bypass grafting.

Eligibility criteria:
inclusion criteria: * patients undergoing bilateral internal thoracic artery harvest for coronary artery bypass surgery exclusion criteria: * inability to speak english or french * inability to complete follow-up visits

Keywords: coronary artery bypass skeletonization internal thoracic artery flow length pain
oral gemifloxacin versus intravenous cefotaxime in treatment of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis

Summary: oral gemifloxacin versus intravenous cefotaxime in treatment of spontaneous bacterial peritonitis

comparative study between the efficacy of oral gemifloxacin and intravenous cefotaxime in treatment of spontaneous bacterial peritonitis

Eligibility criteria:
inclusion criteria: * patients with spontaneous bacterial peritonitis exclusion criteria: * secondary peritonitis
the snores randomized clinical trial

Conditions: PCOS; Sleep Apnea

Summary: randomized clinical trial among women with polycystic ovary syndrome (pcos) who present for fertility treatment to evaluate the impact of screening for obstructive sleep apnea.

the investigators' goal is to perform a randomized clinical trial among women with pcos who present for infertility treatment. our primary outcome is to determine if screening women with pcos, and treating those with confirmed sleep apnea, will lead to more ovulatory cycles. our sub-aims are to describe the rate of osa and sleep symptoms in patients with pcos, to see if current sleep questionnaires correlate to a diagnostic sleep study, to describe the correlation between osa and biomarkers of glucose homeostasis in women with pcos, to investigate health related quality of life between the groups, to compare perinatal outcomes between the groups, and to evaluate the composition of breastmilk among women who choose to breastfeed.

Eligibility criteria:
inclusion criteria * females 18 - 50 years old. * receiving care from an obstetrician / gynecologist or a reproductive endocrinology infertility specialist * polycystic ovarian syndrome defined by the modified rotterdam criteria * able to speak and understand as well as give informed consent in english exclusion criteria * late onset congenital adrenal hyperplasia * cushings disease * androgen-secreting tumors * previous diagnosis of obstructive sleep apnea * current use of over the counter or prescribed sleep medications. * examples of medications that exclude a patient from this study include but are not limited to unisom, ambien or lunesta. * patients who are taking non-prescribed herbal medications for sleep will not be excluded from the study. examples of these include but are not limited to melatonin, chamomile, or valerian. * untreated thyroid disease * prolactin excess * patients with the following medical conditions will be excluded from the study as portable sleep apnea monitors are not indicated in patients with severe pulmonary disease, neuromuscular disease, or congestive heart failure.
targeted drug combined with chop in the treatment of newly diagnosed peripheral t-cell lymphoma

Conditions: Peripheral T-cell Lymphoma

Summary: this prospective，multi-center，open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with chop in treatment of newly diagnosed peripheral t-cell lymphoma.

peripheral t-cell lymphoma (ptcl）is a distinct and heterogeneous histopathologic subtype of non-hodgkin lymphoma (nhl), accounting for \~10%. patients with ptcl still have poor treatment response and prognosis under conventional chop regimen. there is no standard of care for those patients. targeted drugs are warranted in this group of patients to improve survival. this prospective，multi-center，open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with chop in treatment of newly diagnosed peripheral t-cell lymphoma.

Eligibility criteria:
inclusion criteria: * pathologically confirmed peripheral t-cell lymphoma based on 2016 who classification with enough tumor sample for ngs * treatment naive * age ≥ 18 years * must has measurable lesion in ct or pet-ct prior to treatment * ecog 0,1,2 * informed consented exclusion criteria: * alcl,alk positive, nk/t-cell leukemia, adult t-cell lymphoma/leukemia, t-lgl * has accepted localized or systemic anti-lymphoma treatment * has accepted autologous stem cell transplantation before * history of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment * uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * primary cns lymphoma * left ef≤ 50% * lab at enrollment (unless caused by lymphoma): neutrophile\ 2\*uln; creatinine\>1.5\*uln * other uncontrollable medical condition that may that may interfere the participation of the study * not able to comply to the protocol for mental or other unknown reasons * patients with mentally disorders or other reasons unable to fully comply with the study protocol * pregnant or lactation * hiv infection * hbv-dna or hcv-rna positive

Keywords: peripheral t-cell lymphoma targeted therapy